Patiromer Suppliers & Bulk Manufacturers
Available Forms: Sachet
Available Strengths: 8.4 mg
Reference Brands: Veltassa®(US) Generics
Category:
Nephrology
Patiromer 8.4 g Sachet is used to treat hyperkalemia in patients with chronic kidney disease (CKD) or those on RAAS inhibitors. It helps lower elevated potassium levels by binding to potassium in the gastrointestinal tract, reducing the risk of cardiovascular complications.
Patiromer is available in Sachet
and strengths such as 8.4 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Patiromer is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Patiromer can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Patiromer 8.4 g Sachet is a key treatment in nephrology for managing hyperkalemia in patients with chronic kidney disease (CKD) or those on RAAS inhibitors. This potassium-binding medication helps lower elevated potassium levels in the blood, reducing the risk of cardiovascular complications. Available in a convenient 8.4 g sachet form, Patiromer is widely used in hospital and clinical settings across the US and EU. For pharma B2B in these regions, it provides a reliable solution for healthcare providers managing electrolyte imbalances in high-risk patients. Patiromer’s efficacy and safety make it an essential product in nephrology care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing